Novo Nordisk
Novo Nordisk’s Wegovy Pill Launches Strongly Amid Analyst Caution
Wegovy pill; Novo Nordisk; FDA approval; oral GLP-1; obesity drug; Eli Lilly competition
Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field
Novo Nordisk; Aspect; cell therapy; type 1 diabetes; stem cell-derived islet cells; hypoimmune technology
Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26
Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide
JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments
Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide
Novo Nordisk Launches Wegovy Pill in the US with Broad Availability
Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss
Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment
Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1
FDA Approves Novo Nordisk’s Wegovy Pill as First Oral GLP-1 for Weight Management
Novo Nordisk; Wegovy pill; FDA approval; obesity treatment; oral semaglutide
Jesper Høiland Joins Alva Therapeutics’ Board of Directors
Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization
Jesper Høiland Joins Alva Therapeutics’ Board of Directors
Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization
Novo Nordisk’s Amycretin Significantly Reduces Weight and Blood Sugar in Phase 2 Type 2 Diabetes Trial
Novo Nordisk; Amycretin; Type 2 diabetes; Weight loss; HbA1c reduction; GLP-1 agonist; Amylin receptor agonist; Phase 2 clinical trial; Subcutaneous administration; Oral administration